Tag: KDC-MN-088

  • IGF-1 DES

    Truncated IGF-1 analog

    A truncated form of IGF-1 missing the first three residues, with reduced IGFBP binding and increased local potency.

    Abstract

    IGF-1 DES (DES(1-3) IGF-1) is a truncated analog of human IGF-1 missing the first three N-terminal residues (Gly-Pro-Glu). The truncation reduces binding to IGF binding proteins (IGFBPs) and increases the free fraction of the peptide at target tissues, producing approximately 10-fold higher local potency than native IGF-1 at equivalent doses. The compound is sold as a research chemical. Plasma half-life is shorter than IGF-1 LR3 (approximately 20 to 30 minutes for IGF-1 DES vs hours for LR3) due to the absence of the Arg3 modification, but the increased local activity provides higher peak effects per dose. Investigational doses range widely; safety considerations parallel IGF-1 LR3 (chronic IGF-1 elevation effects on cancer risk and acromegalic features).

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.